scholarly journals Pharmacokinetic Studies of (S)-(+)-6-(2-chlorophenyl)-3-cyclopropanecarbonyl-8,11-dimethyl-2,3,4,5-tetrahydro-8H-pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine (R6123). (I). Absorption, Distribution, Metabolism, Excretion and Identification of Metabolites in Beagle Dogs.

1993 ◽  
Vol 8 (2) ◽  
pp. 221-237
Author(s):  
Kazutomi KUSANO ◽  
Shigeru TANAKA ◽  
Teruya KOSAKI ◽  
Shuhei MIYAZAWA ◽  
Kyoichi TADANO ◽  
...  
Keyword(s):  
Pharmacokinetic Studies ◽  
Beagle Dogs

scholarly journals Pharmacokinetic studies of 1.ALPHA.,24(R)-(OH)2D3(TV-02)(5). Plasma level and excretion in beagle dogs.

1990 ◽  
Vol 5 (1) ◽  
pp. 63-69
Author(s):  
Tomohiro OHTA ◽  
Hirohide MIMURA ◽  
Masaru YAMAMOTO ◽  
Mamoru KIYOKI ◽  
Takeo OHBA ◽  
...  
Keyword(s):  
Plasma Level ◽  
Pharmacokinetic Studies ◽  
Beagle Dogs

scholarly journals Pharmacokinetic studies of phloretin in beagle dogs plasma using LC–MS/MS

2017 ◽  
Vol 29 (4) ◽  
pp. 443-447 ◽  
Author(s):  
Libin Wang ◽  
Le Mi ◽  
Tian Feng ◽  
Xueying Liu ◽  
Shengyong Zhang
Keyword(s):  
Pharmacokinetic Studies ◽  
Beagle Dogs

Safety and pharmacokinetic studies of liposomal antioxidant formulations containing N-acetylcysteine,α-tocopherol orγ-tocopherol in beagle dogs

2013 ◽  
Vol 23 (6) ◽  
pp. 419-431 ◽  
Author(s):  
Misagh Alipour ◽  
Panagiotis Mitsopoulos ◽  
Milton G. Smith ◽  
Gordon Bolger ◽  
Kresimir Pucaj ◽  
...  
Keyword(s):  
Pharmacokinetic Studies ◽  
Beagle Dogs

Preclinical Pharmacokinetics Study of a Novel Intravenous Anesthetic ET-26 Hydrochloride

2020 ◽  
Vol 20 (13) ◽  
pp. 1073-1081 ◽  
Author(s):  
Yu Jun Zhang ◽  
ChaoYi Deng ◽  
Jun Yang ◽  
DeYing Gong ◽  
Yi Kang ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Metabolic Pathway ◽  
Glucuronic Acid ◽  
Pharmacokinetic Studies ◽  
Myocardial Performance ◽  
Beagle Dogs ◽  
Preclinical Pharmacokinetics ◽  
Intravenous Anesthetic ◽  
Hypnotic Effect ◽  
T Values

Background: ET-26 hydrochloride is a novel intravenous anesthetic, approved for clinical trials, that produces a desirable sedative-hypnotic effect with stable myocardial performance and mild adrenocortical suppression in rats and beagle dogs. The objective of this study was to assess the absorption, distribution, metabolism, and excretion of ET-26 hydrochloride. Methods: Hepatocytes from human, monkey, dog, rat, and mouse were used to determine the metabolites of ET-26 hydrochloride. Distribution and excretion were assessed in rats and pharmacokinetic studies were performed in beagle dogs. Results: The metabolic pathway and proposed structure of metabolites were fully assessed resulting from the biotransformation reactions of hydrolysis, dehydrogenation, demethylation and glucuronic acid conjugation. The main distribution of the drug was in fat (15067 ± 801 ng/ml) and liver (13647 ± 1126 ng/ml), and the kidney was the primary excretion route (4.47%-11.94%). The Cmax after injection with 1.045 mg/kg, 2.09 mg/kg, and 4.18 mg/kg was 1476.5 ± 138.9 ng/ml, 2846.1 ± 223.3 ng/ml, and 6233.3 ± 238.9 ng/ml, respectively. The t1/2 of the drug was similar across dose groups at 74.8 ± 10.8 min to 81.4 ± 4.2 min. The AUC0-t values were 30208.1 ± 2026.5 min*ng/ml, 62712.8 ± 1808.3 min*ng/ml, and 130465.2 ± 7457.4 min*ng/ml, respectively. Conclusion: The metabolic pathway and the proposed structure of metabolites for ET-26 hydrochloride were fully assessed. The majority of distribution for ET-26 hydrochloride occurs in the fat and liver, while the primary route of excretion for ET-26 hydrochloride is through the kidney. In dogs, pharmacokinetic features of ET-26 hydrochloride had a linear relationship with dosage.

scholarly journals Pharmacokinetics and Safety of Mitragynine in Beagle Dogs

Planta Medica ◽  
2020 ◽  
Vol 86 (17) ◽  
pp. 1278-1285 ◽  
Author(s):  
Elizabeth A. Maxwell ◽  
Tamara I. King ◽  
Shyam H. Kamble ◽  
Kanumuri Siva Rama Raju ◽  
Erin C. Berthold ◽  
...  
Keyword(s):  
Peak Plasma ◽  
Plasma Concentrations ◽  
Compartmental Analysis ◽  
Ultra Performance Liquid Chromatography ◽  
Volume Of Distribution ◽  
Pharmacokinetic Studies ◽  
Beagle Dogs ◽  
Limit Of Quantification ◽  
Significant Information ◽  
Pharmacokinetic Properties

AbstractMitragynine is the most abundant psychoactive alkaloid derived from the leaves of Mitragyna speciosa (kratom), a tropical plant indigenous to regions of Southeast Asia. Mitragynine displays a moderate affinity to opioid receptors, and kratom is often self-prescribed to treat pain and/or opioid addiction. The purpose of this study was to investigate the safety and pharmacokinetic properties of mitragynine in the dog. Single dose oral (5 mg/kg) and intravenous (0.1 mg/kg) pharmacokinetic studies of mitragynine were performed in female beagle dogs. The plasma concentrations of mitragynine were measured using ultra-performance liquid chromatography coupled with a tandem mass spectrometer, and the pharmacokinetic properties were analyzed using non-compartmental analysis. Following intravenous administration, mitragynine showed a large volume of distribution (Vd, 6.3 ± 0.6 L/kg) and high clearance (Cl, 1.8 ± 0.4 L/h/kg). Following oral mitragynine dosing, first peak plasma (Cmax, 278.0 ± 47.4 ng/mL) concentrations were observed within 0.5 h. A potent mu-opioid receptor agonist and active metabolite of mitragynine, 7-hydroxymitragynine, was also observed with a Cmax of 31.5 ± 3.3 ng/mL and a Tmax of 1.7 ± 0.6 h in orally dosed dogs while its plasma concentrations were below the lower limit of quantification (1 ng/mL) for the intravenous study. The absolute oral bioavailability of mitragynine was 69.6%. Administration of mitragynine was well tolerated, although mild sedation and anxiolytic effects were observed. These results provide the first detailed pharmacokinetic information for mitragynine in a non-rodent species (the dog) and therefore also provide significant information for allometric scaling and dose predictions when designing clinical studies.

Simultaneous determination of rabeprazole enantiomers and their four metabolites after intravenous administration in beagle dogs by a stereoselective HPLC-MS/MS method and its application in pharmacokinetic studies

2016 ◽  
Vol 8 (6) ◽  
pp. 1405-1414 ◽  
Author(s):  
Na Cao ◽  
Lei Liu ◽  
Yuan-bin Hao ◽  
Li-li Sun ◽  
Qiao-gen Zou ◽  
...  
Keyword(s):  
Simultaneous Determination ◽  
Intravenous Administration ◽  
Pharmacokinetic Studies ◽  
Beagle Dogs ◽  
Beagle Dog

A sensitive, rapid and stable HPLC-MS/MS method has been developed and validated for the determination of rabeprazole enantiomers and their four metabolites in beagle dog.

Subchronic toxicity and plasma pharmacokinetic studies on wogonin, a natural flavonoid, in Beagle dogs

2009 ◽  
Vol 124 (2) ◽  
pp. 257-262 ◽  
Author(s):  
Jian Peng ◽  
Qi Qi ◽  
Qidong You ◽  
Rong Hu ◽  
Wenyuan Liu ◽  
...  
Keyword(s):  
Pharmacokinetic Studies ◽  
Beagle Dogs ◽  
Subchronic Toxicity ◽  
Plasma Pharmacokinetic

scholarly journals Quantitation of Apremilast in Beagle Dogs Plasma by UPLC-MS-MS and Its Application to Pharmacokinetic Studies

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Wei Xiong ◽  
Ling Wang ◽  
Haiyan Zhang ◽  
Xiaoqiu Tao ◽  
Xuehua Jiang ◽  
...  
Keyword(s):  
Internal Standard ◽  
Gradient Elution ◽  
Ultra Performance Liquid Chromatography ◽  
Ammonium Formate ◽  
Pharmacokinetic Studies ◽  
Beagle Dogs ◽  
Beagle Dog ◽  
Dog Plasma ◽  
Liquid Chromatography Tandem Mass

A sensitive and selective ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS-MS) method for the determination of apremilast in beagle dog plasma has been developed and successfully validated in the current study. Clopidogrel was employed as an internal standard (IS), and liquid-liquid extraction by tert-butylmethyl ether was used for sample preparation. Chromatographic separation was achieved on a UPLC BEH Shield RP18 column (50 mm × 2.1 mm, 1.7 μm) with 5 mM ammonium formate water and 5 mM ammonium formate methanol as the mobile phase with gradient elution. Calibration plots were linear in the range of 2–3000 ng/mL for apremilast in beagle dog plasma. Mean recoveries of apremilast in beagle dogs plasma ranged from 87.4% to 97.4%. The intrarun and interrun precision was less than 6% and 9%, respectively, with the accuracy between 92.4% and 101.1%. The method has also been successfully applied in the pharmacokinetics study of apremilast. The mean t1/2Z was 5.41 h for 30 mg·day−1 for beagle dogs after oral administration. The AUC0-t increased linearly from 3.51 to 1802.13  μ g   L − 1 ∗ h after administration of single doses.

scholarly journals Pharmacokinetic Studies of Sustained-Release Depot of Dexamethasone in Beagle Dogs

2016 ◽  
Vol 32 (9) ◽  
pp. 595-600 ◽  
Author(s):  
Charles Blizzard ◽  
Ankita Desai ◽  
Arthur Driscoll
Keyword(s):  
Sustained Release ◽  
Pharmacokinetic Studies ◽  
Beagle Dogs
Sign in / Sign up

Export Citation Format

Share Document